However, the prevalence of APOE4 is markedly higher among individuals with AD, being detected in 55–75% of those with AD dementia, around 57% of individuals with prodromal AD, and approximately 55% of those in the preclinical stage of the disease [37]. This evidence concerns the gene APOE and dementia.